De novo drug design with desired biological activities
is crucial
for developing novel therapeutics for patients. The drug development
process is time- and resource-consuming, and it has a low probability
of success. Recent advances in machine learning and deep learning
technology have reduced the time and cost of the discovery process
and therefore, improved pharmaceutical research and development. In
this paper, we explore the combination of two rapidly developing fields
with lead candidate discovery in the drug development process. First,
artificial intelligence has already been demonstrated to successfully
accelerate conventional drug design approaches. Second, quantum computing
has demonstrated promising potential in different applications, such
as quantum chemistry, combinatorial optimizations, and machine learning.
This article explores hybrid quantum-classical generative adversarial
networks (GAN) for small molecule discovery. We substituted each element
of GAN with a variational quantum circuit (VQC) and demonstrated the
quantum advantages in the small drug discovery. Utilizing a VQC in
the noise generator of a GAN to generate small molecules achieves
better physicochemical properties and performance in the goal-directed
benchmark than the classical counterpart. Moreover, we demonstrate
the potential of a VQC with only tens of learnable parameters in the
generator of GAN to generate small molecules. We also demonstrate
the quantum advantage of a VQC in the discriminator of GAN. In this
hybrid model, the number of learnable parameters is significantly
less than the classical ones, and it can still generate valid molecules.
The hybrid model with only tens of training parameters in the quantum
discriminator outperforms the MLP-based one in terms of both generated
molecule properties and the achieved KL divergence. However, the hybrid
quantum-classical GANs still face challenges in generating unique
and valid molecules compared to their classical counterparts.